NO20072035L - Memantin for behandling av adferdsforstyrrelser hos barn - Google Patents

Memantin for behandling av adferdsforstyrrelser hos barn

Info

Publication number
NO20072035L
NO20072035L NO20072035A NO20072035A NO20072035L NO 20072035 L NO20072035 L NO 20072035L NO 20072035 A NO20072035 A NO 20072035A NO 20072035 A NO20072035 A NO 20072035A NO 20072035 L NO20072035 L NO 20072035L
Authority
NO
Norway
Prior art keywords
memantine
children
treatment
behavioral disorders
disorder
Prior art date
Application number
NO20072035A
Other languages
English (en)
Norwegian (no)
Inventor
Sandeep Gupta
Jeffrey Jonas
Pradeep K Banerjee
Allison Mann
Hans-Joerg Moebius
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35445934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072035(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of NO20072035L publication Critical patent/NO20072035L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20072035A 2004-09-23 2007-04-20 Memantin for behandling av adferdsforstyrrelser hos barn NO20072035L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61260004P 2004-09-23 2004-09-23
PCT/US2005/034199 WO2006034465A1 (en) 2004-09-23 2005-09-23 Memantine for the treatment of childhood behavioral disorders

Publications (1)

Publication Number Publication Date
NO20072035L true NO20072035L (no) 2007-06-13

Family

ID=35445934

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072035A NO20072035L (no) 2004-09-23 2007-04-20 Memantin for behandling av adferdsforstyrrelser hos barn

Country Status (16)

Country Link
US (2) US20060079582A1 (pt)
EP (1) EP1799224A1 (pt)
JP (1) JP2008514620A (pt)
KR (1) KR20070046185A (pt)
CN (1) CN101374525A (pt)
AR (1) AR052643A1 (pt)
AU (1) AU2005286672B2 (pt)
BR (1) BRPI0515560A (pt)
CA (1) CA2578953A1 (pt)
EA (1) EA012036B1 (pt)
IL (1) IL182105A0 (pt)
MX (1) MX2007003267A (pt)
NO (1) NO20072035L (pt)
TW (1) TW200626160A (pt)
WO (1) WO2006034465A1 (pt)
ZA (1) ZA200702130B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
WO2008005534A2 (en) * 2006-07-06 2008-01-10 Forest Laboratories, Inc. Orally dissolving formulations of memantine
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
WO2009004440A2 (en) * 2007-06-29 2009-01-08 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
US20090247644A1 (en) * 2008-03-28 2009-10-01 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
HUE032888T2 (hu) * 2008-12-08 2017-11-28 Biocodex Vegyületek és eljárások autizmus spektrum zavarok kezelésére
IT1396556B1 (it) * 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
WO2014015047A1 (en) 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
UA107653U (uk) * 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
KR101424514B1 (ko) * 2013-01-02 2014-07-31 건국대학교 산학협력단 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도
EP2948135B1 (en) * 2013-01-25 2019-01-02 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
WO2014153180A1 (en) * 2013-03-14 2014-09-25 Michela Gallagher Methods and compositions for improving cognitive function
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
PT3297644T (pt) * 2015-05-22 2022-03-30 Univ Arizona State Métodos para tratar distúrbios do espetro do autismo e sintomas associados
EP3310785B1 (en) 2015-06-19 2024-11-20 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2018037306A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3661492B1 (en) * 2017-08-01 2024-12-25 Stuart A. Lipton Nitrosynapsin for use in treating autism spectrum disorder
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
EP3713558B1 (en) 2017-11-22 2024-09-11 Panorama Research Inc. Aminoadamantyl nitrate compounds and their use to treat cns disorders
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
MX2020013927A (es) 2018-06-19 2021-03-02 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
SG11202104378SA (en) 2018-11-19 2021-05-28 Zogenix International Ltd Methods of treating rett syndrome using fenfluramine
EP4288150A4 (en) * 2021-02-03 2025-05-07 The General Hospital Corporation METHODS FOR TREATING AUTISM SPECTRUM DISORDERS
KR20250136397A (ko) * 2023-01-27 2025-09-16 하이로리스 디벨롭먼츠 에스에이 쓴맛 약물을 위한 맛 차폐제로서 비타민 e tpgs 의 용도

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES413944A1 (es) * 1972-04-20 1976-06-01 Merz & Co Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5.
HU169986B (pt) * 1972-12-07 1977-03-28
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
DE58905637D1 (de) * 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6326226B1 (en) * 1997-07-15 2001-12-04 Lg. Philips Lcd Co., Ltd. Method of crystallizing an amorphous film
EP1047436B1 (en) * 1998-01-13 2009-10-21 Synchroneuron, LLC N-acetylhomotaurinates for use in treating hyperkinesias
AU4517201A (en) * 1999-12-08 2001-06-18 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
US20060167032A1 (en) * 2002-01-16 2006-07-27 Galer Bradley S Pharmaceutical composition and method for treating disorders of the central nervous system
AU2003251993A1 (en) * 2002-07-19 2004-02-09 Inge Grundke-Iqbal NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease

Also Published As

Publication number Publication date
TW200626160A (en) 2006-08-01
JP2008514620A (ja) 2008-05-08
AU2005286672A1 (en) 2006-03-30
WO2006034465A8 (en) 2006-06-08
KR20070046185A (ko) 2007-05-02
AU2005286672B2 (en) 2009-03-12
AR052643A1 (es) 2007-03-28
MX2007003267A (es) 2007-05-23
CN101374525A (zh) 2009-02-25
BRPI0515560A (pt) 2008-07-29
US20060079582A1 (en) 2006-04-13
EA200700708A1 (ru) 2007-08-31
EA012036B1 (ru) 2009-06-30
IL182105A0 (en) 2007-07-24
CA2578953A1 (en) 2006-03-30
ZA200702130B (en) 2008-09-25
WO2006034465A1 (en) 2006-03-30
EP1799224A1 (en) 2007-06-27
US20100081723A1 (en) 2010-04-01

Similar Documents

Publication Publication Date Title
NO20072035L (no) Memantin for behandling av adferdsforstyrrelser hos barn
WO2005037203A3 (en) Methods and reagents for the treatment of immunoinflammatory disorders
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
NO20080246L (no) Anti-IGF1R-antistofformuleringer
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
ATE534752T1 (de) Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders
NO20083147L (no) Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse
DOP2009000269A (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
PL2341344T3 (pl) Sposób diagnozowania wielotorbielowatości nerek
CY1110620T1 (el) Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας
BRPI0510224A (pt) métodos de prevenção de doença autoimunológica e artigo industrializado
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
BRPI0416812A (pt) métodos e reagentes para o tratamento de desordens inflamatórias
WO2008100727A3 (en) High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
EA200701995A1 (ru) Способы уменьшения кальцификации
WO2006059252A3 (en) Methods and fluorinated compositions for treating amyloid-related diseases
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
TW200740441A (en) Methods and reagents for the treatment of inflammatory disorders
EP1899726A4 (en) METHODS FOR DIAGNOSING AND TREATING CEREBROVASCULAR EVENTS BASED ON NR2 PEPTIDES
MX2020002008A (es) Tratamientos antivirales intravenosos.
WO2007095352A3 (en) Diagnosis and treatment of attentional disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application